Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease
Qingxin Li, CongBao Kang
Microorganisms (2020) Vol. 8, Iss. 8, pp. 1250-1250
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
Sk. Abdul Amin, Suvankar Banerjee, Kalyan Ghosh, et al.
Bioorganic & Medicinal Chemistry (2020) Vol. 29, pp. 115860-115860
Open Access | Times Cited: 175
The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Qing Hu, Yuan Xiong, Guanghao Zhu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 144
Synthesis of New Organoselenium-Based Succinanilic and Maleanilic Derivatives and In Silico Studies as Possible SARS-CoV-2 Main Protease Inhibitors
Saad Shaaban, Yasair S. Al-Faiyz, Ghayah M. Alsulaim, et al.
Inorganics (2023) Vol. 11, Iss. 8, pp. 321-321
Open Access | Times Cited: 51
The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors
Anja Pišlar, Ana Mitrović, Jerica Sabotič, et al.
PLoS Pathogens (2020) Vol. 16, Iss. 11, pp. e1009013-e1009013
Open Access | Times Cited: 105
What coronavirus 3C‐like protease tells us: From structure, substrate selectivity, to inhibitor design
Muya Xiong, Haixia Su, Wenfeng Zhao, et al.
Medicinal Research Reviews (2021) Vol. 41, Iss. 4, pp. 1965-1998
Open Access | Times Cited: 98
Calendulaglycoside A showing potential activity against SARS-CoV-2 main protease: Molecular docking, molecular dynamics, and SAR studies
Ahmed A. Zaki, Ahmed Ashour, Sameh S. Elhady, et al.
Journal of Traditional and Complementary Medicine (2021) Vol. 12, Iss. 1, pp. 16-34
Open Access | Times Cited: 89
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
Uttpal Anand, Shweta Jakhmola, Omkar Indari, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 78
Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CLpro: Inhibition potentials, covalent binding sites and inhibitory mechanisms
Yuan Xiong, Guanghao Zhu, Yani Zhang, et al.
International Journal of Biological Macromolecules (2021) Vol. 187, pp. 976-987
Open Access | Times Cited: 59
Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
C. Joaquín Cáceres, Stivalis Cárdenas-García, Silvia Carnaccini, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 57
Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2
Juliana C. Ferreira, Samar Fadl, Wael M. Rabeh
Journal of Biological Chemistry (2022) Vol. 298, Iss. 6, pp. 102023-102023
Open Access | Times Cited: 44
Advances in oligosaccharides production from algal sources and potential applications
Pitchurajan Krishna Perumal, Cheng‐Di Dong, Ajeet Singh Chauhan, et al.
Biotechnology Advances (2023) Vol. 67, pp. 108195-108195
Closed Access | Times Cited: 28
Computational Discovery of Novel Imidazole Derivatives as Inhibitors of SARS-CoV-2 Main Protease: An Integrated Approach Combining Molecular Dynamics and Binding Affinity Analysis
Benjamin Ayodipupo Babalola, Abayomi Emmanuel Adegboyega
COVID (2024) Vol. 4, Iss. 6, pp. 672-695
Open Access | Times Cited: 7
Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity
Ying Li Weng, Shiv Rakesh Naik, Nadia Dingelstad, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 49
Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
Jonathan Rawson, Alice Duchon, Olga A. Nikolaitchik, et al.
Viruses (2021) Vol. 13, Iss. 2, pp. 173-173
Open Access | Times Cited: 44
Drug repurposing in psoriasis, performed by reversal of disease-associated gene expression profiles
Faheem Ahmed, Son Gi Ho, Anupama Samantasinghar, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 6097-6107
Open Access | Times Cited: 32
Early identification of breakthrough research from sleeping beauties using machine learning
Xin Li, Xiaodi Ma, Feng Ye
Journal of Informetrics (2024) Vol. 18, Iss. 2, pp. 101517-101517
Closed Access | Times Cited: 5
In Silico Tuning of Binding Selectivity for New SARS-CoV-2 Main Protease Inhibitors
Feng Wang, Vladislav Yu. Vasilyev
Computer Methods and Programs in Biomedicine (2025) Vol. 262, pp. 108678-108678
Open Access
Possible Beneficial Actions of Caffeine in SARS-CoV-2
Bianca S. Romero-Martínez, Luis M. Montaño, Héctor Solís‐Chagoyán, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5460-5460
Open Access | Times Cited: 35
Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19
Joyce van de Leemput, Zhe Han
Molecular and Cellular Biology (2021) Vol. 41, Iss. 9
Open Access | Times Cited: 33
Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19
Jianwei Zhang, Yuan Xiong, Feng Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 228, pp. 114030-114030
Open Access | Times Cited: 32
Synthesis, spectroscopic (FT-IR, FT-Raman, NMR), reactivity (ELF, LOL and Fukui) and docking studies on 3-(2‑hydroxy-3‑methoxy-phenyl)-1-(3-nitro-phenyl)-propenone by experimental and DFT methods
Shivaraj B. Radder, Raveendra Melavanki, Umesharaddy Radder, et al.
Journal of Molecular Structure (2022) Vol. 1255, pp. 132443-132443
Closed Access | Times Cited: 26
Pro108Ser mutation of SARS-CoV-2 3CLpro reduces the enzyme activity and ameliorates the clinical severity of COVID-19
Kodai Abe, Yasuaki Kabe, Susumu Uchiyama, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 25
The Natural Products Withaferin A and Withanone from the Medicinal HerbWithania somniferaAre Covalent Inhibitors of the SARS-CoV-2 Main Protease
Shayantani Chakraborty, Dibyendu Mallick, Mausumi Goswami, et al.
Journal of Natural Products (2022) Vol. 85, Iss. 10, pp. 2340-2350
Closed Access | Times Cited: 23
Multiscale Simulations of the Covalent Inhibition of the SARS-CoV-2 Main Protease: Four Compounds and Three Reaction Mechanisms
Bella L. Grigorenko, Igor V. Polyakov, Maria G. Khrenova, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 24, pp. 13204-13214
Open Access | Times Cited: 15
Synergistic effects of steric constraints and non-covalent interactions in copper(ii) chloro-nitro-benzoato complexes: synthesis, structural characterization, theoretical investigations, antimicrobial studies, and molecular docking analyses
Chetan Chauhan, Santosh Kumar, Rajesh Kumar, et al.
New Journal of Chemistry (2024) Vol. 48, Iss. 9, pp. 3829-3848
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top